Halozyme Therapeutics, Inc.
- Jurisdiction
United States - LEI
529900242I3SV9AGM753 - ISIN
US40637H1095 (HALO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€109.12 95.8% undervalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. Read full profile
Fundamentals
- Net revenue
€1.01B - Gross margin
84.2% - EBIT
€582.29M - EBIT margin
57.9% - Net income
€475.33M - Net margin
47.3%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
|
|
|
|
| Connaughton Bernadette | N/A |
|
|
|
|
| Torley Helen | PRESIDENT AND CEO |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | April 7, 2025 | $1.00K–$15.00K |
| Josh Gottheimer | October 3, 2024 | $1.00K–$15.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 7, 2024 (Q1 2024)